A comparison between the clinical disease severity and smoking status was analyzed by the SPSS 22.0 software statistic program at a significance level of p
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Aim: This study was conducted to assess smoking status and COVID-19 clinical severity in health professionals of a pandemic health center.Methods: A retrospective study design based on data reports of a tertiary hospital between March 2020 and June 2020 was realized.
📊
Key Findings & Data:Aim: This study was conducted to assess smoking status and COVID-19 clinical severity in health professionals of a pandemic health center.Methods: A retrospective study design based on data reports of a tertiary hospital between March 2020 and June 2020 was realized.
💡
Conclusion & Impact:A comparison between the clinical disease severity and smoking status was analyzed by the SPSS 22.0 software statistic program at a significance level of p
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters
Abstract
Aim: This study was conducted to assess smoking status and COVID-19 clinical severity in health professionals of a pandemic health center.Methods: A retrospective study design based on data reports of a tertiary hospital between March 2020 and June 2020 was realized. A comparison between the clinical disease severity and smoking status was analyzed by the SPSS 22.0 software statistic program at a significance level of p
Özet
Amaç: Bu çalışma, bir pandemi sağlık merkezinde çalışan sağlık profesyonellerinde sigara içme durumunu ve COVID-19 klinik şiddetini değerlendirmek için yapılmıştır.Yöntem: Mart 2020 ile Haziran 2020 arasında üçüncü basamak bir hastanenin veri raporlarına dayanarak geriye dönük bir çalışma tasarımı gerçekleştirilmiştir. Klinik hastalık şiddeti ve sigara içme durumu arasındaki karşılaştırma SPSS 22.0 yazılım istatistik programı ile anlamlılık düzeyi p
🔖
Cite This Article
BASAT, O., TANIMLI, E., BAŞPINAR, M. M., KESKİN, G. (2022). Evaluation of Smoking and Asymptomatic COVID-19 Disease in HealthProfessionals. Eurasian Journal of Family Medicine, Cilt: 9 - Sayı: 4, 244–250. https://ajindex.com/articles/508329
Maio S, Baldacci S, Carrozzi L, Pistelli F, Simoni M, Angino A, et al. 18-yr cumulative incidence of respiratory/allergic symptoms/diseases and risk factors in the Pisa epidemiological study. Respir Med 2019;158:33-41. doi: 10.1016/j.rmed.2019.09.013
Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int J Environ Res Public Health2018;15(5):1033. doi: 10.3390/ijerph15051033
Berlin I, Thomas D, Le Faou A-L, Cornuz J. COVID-19 and smoking. Nicotine Tob Res 2020: ntaa059. doi: 10.1093/ntr/ntaa059
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92(4):401-2. doi: 10.1002/jmv.25678
Kutlu R. What we have learned about the new coronavirus pandemic, current diagnostic and therapeutic approaches and the situation in Turkey. TJFMPC 2020;14(2):329-44
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. doi: 10.1056/NEJMoa2002032
Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tobacco Induced Diseases2020;18:1-4. doi: 10.18332/tid/119324
García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol 2020;11:1441. doi: 10.3389/fimmu.2020.01441
Padula WV. Why only test symptomatic patients? Consider random screening for COVID-19. Appl Health Econ Health Policy 2020:1-2. doi: 10.1007/s40258-020-00579-4
Uysal MA, Kadakal F, Karsidag C, Bayram NG, Uysal O, Yilmaz V, et al. Fagerstrom test for nicotine dependence: reliability in a Turkish sample and factor analysis. Tuberk Toraks 2004;52(2):115-21
National Institutes of Health [Internet]. COVID-19 treatment guidelines. Potential antiviral drugs under evaluation for the treatment of COVID-19 [cited 2020 May 20]. Available from:
Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics2020;145(6):e20200702. doi: 10.1542/peds.2020-0702
Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020;94:154-5. doi: 10.1016/j.ijid.2020.03.020